NCT05813678 - A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace) | Biotech Hunter

Enrollment

450

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

November 1, 2033

Study Completion Date

November 1, 2033

Conditions

Phenylketonuria (PKU)

Interventions

DRUG

Pegvaliase

This is an uncontrolled, single-cohort, Phase 4 observational study not falling under the definition of an Applicable Clinical Trial (ACT) (i.e., non-interventional).

Trial Locations (16)

15224

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

46202

RECRUITING

Indiana University School of Medicine, Indianapolis

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

60611

RECRUITING

Northwestern University, Chicago

70118

RECRUITING

Tulane University Medical Center, New Orleans

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

80045

RECRUITING

University of Colorado, Aurora

97239

RECRUITING

Oregon Health and Science University, Portland

Unknown

RECRUITING

Hospital Carl-Thiem-Klinikum Cottbus, Cottbus

RECRUITING

Universitaetsklinikum Hamburg Eppendorf, Hamburg

RECRUITING

Universitätsklinikum Münster (UKM)-Pädiatrische Universitätsklinik Münster, Münster

RECRUITING

Universität Ulm, Ulm

RECRUITING

Policlinico Sant'orsola Malpighi, Bologna

RECRUITING

University Hospital Careggi, Florence

RECRUITING

Ospedale San Paolo, Milan

RECRUITING

"Azienda Ospedaliera Universitaria Federico II Dipartimento di Pediatria", Naples